Tryp Therapeutics To Present at Oppenheimer Fall Healthcare Summit

H.C. WAINWRIGHT GLOBAL INVESTMENT CONFERENCE

TRYP THERAPEUTICS TO PRESENT AT THE CANACCORD ANNUAL GROWTH CONFERENCE

Tryp Therapeutics to Host Q3 Investor Day on July 29, 2021

San Diego, California--(Newsfile Corp. - July 15, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, announced today that it will host their Q3 Investor Day on July 29, 2021 at 9:00 a.m. PDT.

The event will include a presentation by Tryp's management team to discuss updates on its Psilocybin-for-Neuropsychiatric Disorders (PFN^TM) program as well as upcoming milestones for 2021 and beyond. The presentation will be followed with a Q&A session including Greg McKee, Chairman and Chief Executive Officer; Luke Hayes, Chief Financial Officer; and Jim Gilligan, Ph.D., President and Chief Science Officer. A replay of the event will be available for 30 days following the event, and available on our website.

"I am excited to showcase the transformative work that Tryp Therapeutics is doing in collaboration with our academic research partners such as the University of Michigan and the University of Florida," commented Greg McKee, Chairman and CEO of Tryp. "The next six months represent an important stage in development for us as we initiate multiple Phase 2a clinical trials and move closer to providing additional treatment options for the millions of patients suffering from a variety of chronic pain diseases and eating disorders."

Webinar Details:

When: Thursday, July 29^th, 2021
Time: 9:00 a.m. PDT
Please Register HERE

Please also sign up on Tryp's website to receive updates from the Company and information on future investor events.

For any questions about the event, please contact us at:
T: 1-833-811-TRYP (8797)
E: investors@tryptherapeutics.com
W: www.tryptherapeutics.com

TRYP THERAPEUTICS TO PRESENT AT THE LADENBURG THALMANN 2021 HEALTHCARE CONFERENCE

San Diego, California--(Newsfile Corp. - June 8, 2021) -  Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) (FSE: 8FW) ("Tryp"), a pharmaceutical company focused on developing compounds for diseases with unmet medical needs through accelerated regulatory pathways, announced today that it is presenting at the Ladenburg Thalmann Healthcare Conference. The conference will be held virtually on July 13 and 14. Greg McKee, Chairman and CEO; Jim Gilligan, President and Chief Science Officer; and Luke Hayes, CFO, will provide an overview of Tryp's business and its pipeline followed by a brief analyst-led fireside chat.

Details of the presentation are as follows:

Date: Tuesday, July 13, 2021
Time: 3:00 - 3:25 p.m. EDT
Location: Virtual
Replay: Ladenburg Thalmann 2021 Healthcare Conference

Tryp Therapeutics to Present at the Psyched 21 Conference

TRYP THERAPEUTICS TO SPEAK & PRESENT AT THE PSYCHED INVESTOR SUMMIT

TRYP THERAPEUTICS TO PRESENT AT THE PSYCHEDELIC OPPORTUNITY SUMMIT

TRYP THERAPEUTICS TO PRESENT AT THE H.C. WAINWRIGHT PSYCHEDELICS CONFERENCE

Details of the presentation are as follows:

Date:                Thursday, June 17^th, 2021

Time:                Tryp’s presentation will be available to access beginning at 7:00 a.m. EDT

Registration:   https://hcwevents.com/psychedelics/

TRYP THERAPEUTICS TO PRESENT AT THE STIFEL GMP HEALTHCARE CONFERENCE

La Jolla, California - February 24, 2021 -  Tryp Therapeutics (CSE: TRYP) ("Tryp" or the "Company") a pharmaceutical company focused on identifying and developing clinical-stage compounds for diseases with high unmet medical needs, announced today the company has been invited to present at the Stifel GMP Healthcare Conference: Healthcare Psychedelics: Addressing the Global Mental Health Crisis.

Commencing on March 11, 2021, the virtual conference will host a series of in-depth presentations with leading industry experts who will discuss how their companies are impacting and shaping the future of mental health care. 

Details for Tryp’s presentation include:

Date:                     March 11, 2021

Time:                    10:40 – 11:10 am EST 

Participants:        Tryp Therapeutics Inc. | Jim Kuo, CEO

Canaccord Psychedelic Investment Conference

EDISON Global Healthcare Conference

Tryp Therapeutics, a leading pharmaceutical company focused on identifying and developing clinical-stage compounds for diseases with high unmet medical needs, has been invited to present at the EDISON Global Heathcare Conference.